018561292

WuXi XDC The Bioconjugation Leader

---

September 19, 2021

Trademark Summary

The trademark application WuXi XDC The Bioconjugation Leader was filed by WuXi XDC Cayman Inc., a corporation established under the laws of the Cayman Islands (the "Applicant"). The application was published for oppositions on October 28, 2021, and it was registered by office on February 4, 2022 without any oppositions.

The application was filed in English (Italian was selected as the second language).

---

Goods And Services

• The mark was filed in class 5 with following description of goods:
  
  1. Pharmaceutical preparations
  2. Chemico-pharmaceutical preparations
  3. Drugs for medical purposes
  4. Biological preparations for medical purposes
  5. Chemical preparations for pharmaceutical purposes
  6. Medicines for human purposes
  7. Chemical preparations for medical purposes
  8. Biochemical medicines
  9. Antibody drug conjugate
  10. Medicines for human purposes bioconjugate drugs.
• The mark was filed in class 40 with following description of goods:
  
  1. Biomanufacturing for others, namely, manufacturing of biopharmaceuticals using biological organisms in the manufacturing process
  2. Custom manufacture of biopharmaceuticals by pharmaceutical compounders
  3. Manufacturing services for others in the field of biopharmaceuticals.
• The mark was filed in class 42 with following description of goods:
  
  1. Biomedical research services
  2. Development of pharmaceutical preparations and medicines
  3. Drug discovery services
  4. Laboratory research services relating to pharmaceuticals
  5. Pharmaceutical drug development services
  6. Pharmaceutical research services
  7. Product development for others
  8. Product quality testing services
  9. Product safety testing services
  10. Providing medical and scientific research information in the fields of pharmaceuticals and genetics
  11. Research and development of new products for others
  12. Research and development services in the field of antibodies
  13. Research and development services in the field of bioconjugated drugs
  14. Research, development, engineering and testing services in the fields of immune pharmaceuticals and vaccines
  15. Testing, inspection, research, or development of pharmaceutical preparations for gene therapy.